Boston Scientific Launches Interlock-35 Fibered IDC Occlusion System

June 30, 2011—Boston Scientific Corporation (Natick, MA) announced the immediate launch of the Interlock-35 fibered interlocking detachable coil (IDC) occlusion system in the United States and Europe. Earlier this year, the system received US Food and Drug Administration clearance and European CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.

According to the company, the Interlock-35 IDC system consists of a 0.035-inch detachable coil with an interlocking connection between the coil and delivery wire, which is designed for placement control, including the ability to advance, retract, and reposition the coil before final deployment in the vessel. The coil is detached by pushing the detachment zone beyond the distal end of the 5-F delivery catheter. The platinum coil is constructed of a dense network of synthetic fibers and is designed for thrombogenicity and rapid stasis.

“Compatibility with 5-F catheters allows for placement of larger coils, which can help achieve peripheral embolization with fewer coils, potentially reducing procedure times,” commented Sally Mitchell, MD. “The Interlock-35 coil provides excellent occlusive power while allowing precise retrievable placement, representing a major advantage over standard 0.035-inch pushable coil technology.”

Boston Scientific stated that the Interlock-35 fibered IDC occlusion system is available in 31 configurations that include coil lengths from 4 to 40 cm, diameters from 3 to 20 mm, and three shapes (cube, two-dimensional helical, and diamond) to treat diverse vessel anatomy. The Interlock-35 joins the 0.018-inch Interlock fibered IDC coils in Boston Scientific's Interlock coil portfolio to provide 50 different coils to optimize peripheral embolization procedures, the company stated.